AstraZeneca partner Pieris ends work on HER2 drug tested in combo with Eli Lilly, Seagen cancer meds

Kyle LaHucik

Senior Reporter

As Pieris Pharmaceuticals favors an AstraZeneca-partnered program in asthma, and because the mid-stage study is taking longer than expected, the biotech is deciding to end …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca partner Pieris ends work on HER2 drug tested in combo with Eli Lilly, Seagen cancer meds

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As­traZeneca part­ner Pieris ends work on HER2 drug test­ed in com­bo with Eli Lil­ly, Seagen can­cer meds

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

AstraZeneca partner Pieris ends work on HER2 drug tested in combo with Eli Lilly, Seagen cancer meds

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence